ArticleTranslational andrology and urology2026
Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In recent years, perioperative-sequential therapies have arisen for muscle-invasive bladder cancer (MIBC) treatment strategies. We are able to select more variable regimens for bladder cancer patients. This study aims to compare clinical outcomes in patients with MIBC who underwent robot-assisted radical cystectomy (RARC) followed by adjuvant nivolumab versus those who did not receive it. Methods: This retrospective single-center study included 60 patients with MIBC who underwent RARC between January 2017 and September 2025. Thirty patients who received adjuvant nivolumab (Nivo group), and 30 patients who did not (no-Nivo group). Disease-free survival (DFS), cancer-specific survival (CSS), and immune-related adverse events (irAEs) were evaluated. Survival analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression models. Inverse probability of treatment weighting was used to adjust for baseline characteristics. Results: Median DFS was significantly longer in the Nivo compared with no-Nivo group [26.0 Conclusions: Adjuvant nivolumab significantly improved DFS in patients with high-risk MIBC in real-world practice; however, patients with pN+ remained at high risk for recurrence despite nivolumab, suggesting the need for more intensive therapeutic strategies in this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.